Letters sent to healthcare professionals in September 2017

Letters were sent in September about Dacogen (decitabine), Eperzan鈻�(albiglutide), ERWINASE, ReoPro (abciximab), and recombinant human erythropoietins.

From:
Medicines and Healthcare products Regulatory Agency
Published
26 October 2017
Therapeutic area:
Cancer, Cardiovascular disease and lipidology, Endocrinology, diabetology and metabolism, Haematology and oncology, Paediatrics and neonatology and Urology and nephrology

In September 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

  • Dacogen (decitabine) 50 mg, powder for concentrate for solution for infusion 鈥�

  • Eperzan鈻�(albiglutide): global discontinuation of medicine 鈥�

  • ERWINASE from BATCH 184G*

  • ReoPro (abciximab) 2 mg/mL solution for injection or infusion:

  • Recombinant human erythropoietins:

Article citation: Drug Safety Update volume 11, issue 3; October 2017: 5.

Updates to this page

Published 26 October 2017